SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI)
Fowler et al., NCT04344184, SAFE EVICT CORONA-ALI,
NCT04344184
RCT 47 ICU patients showing no significant differences with vitamin C treatment.
Although the 19% lower mortality is not statistically significant, it is consistent with the significant 19% lower mortality
[9‑27%] from meta analysis of the
45 mortality results to date.
Standard of Care (SOC): SOC for COVID-19 in the study country,
the USA, is
very poor with
very low average efficacy for approved treatments
1.
Only expensive, high-profit treatments were approved. Low-cost treatments were excluded, reducing the probability of treatment—especially early—due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
This may explain in part the very high mortality seen in this study.
Results may differ in countries with improved SOC.
This study is excluded in the after exclusion results of meta
analysis:
very late stage, ICU patients.
|
risk of death, 18.8% lower, RR 0.81, p = 0.75, treatment 5 of 22 (22.7%), control 7 of 25 (28.0%), NNT 19.
|
|
relative WHO status, 1.7% worse, RR 1.02, p = 0.28, treatment mean 3.05 (±0.22) n=21, control mean 3.0 (±0.0) n=23, day 27.
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Fowler et al., 4 Apr 2024, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial
NCT04344184 (history) (SAFE EVICT CORONA-ALI).
